0000000000140618

AUTHOR

G Di Perri

showing 6 related works from this author

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohor…

2015

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the i…

Genetics and Molecular Biology (all)MaleChronic HepatitisHepacivirusRibavirin/adverse effectsAsthenia/chemically inducedHepacivirusPolyethylene GlycolBiochemistryPolyethylene GlycolsBody Mass IndexChronic Liver Disease0302 clinical medicineNeutropenia/chemically inducedInterferon-alpha/adverse effectsMedicineChroniclcsh:ScienceLiver Diseasesvirus diseasesAntiviral Agents/adverse effectsCohortScience & Technology - Other Topics030211 gastroenterology & hepatologyDrug Therapy CombinationCohort studyHumanmedicine.medical_specialtyAlpha interferonGastroenterology and HepatologyAntiviral AgentsMicrobiologyDose-Response Relationship03 medical and health sciencesPharmacotherapyHepatitis C Chronic/drug therapyDose Prediction MethodsDrug TherapyAnemia/chemically inducedHumansHemoglobinAgedMedicine and health sciencesBiochemistry Genetics and Molecular Biology (all)HepaciviruScience & TechnologyDose-Response Relationship DrugFlaviviruseslcsh:ROrganismsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseaseschemistryAgricultural and Biological Sciences (all)Withholding TreatmentAstheniaImmunologyProportional Hazards Modellcsh:QHuman medicineRNA virusesPhysiologylcsh:MedicinePeginterferon-alfaPolyethylene Glycols/adverse effectsAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Cohort Studieschemistry.chemical_compoundOutcome Assessment Health CareMedicine and Health Sciences030212 general & internal medicineViralPathology and laboratory medicineMultidisciplinarybiologyHepatitis C virusPharmaceuticsMedicine (all)AnemiaHepatitis CHematologyRecombinant ProteinOutcome Assessment (Health Care)/methodsMiddle AgedMedical microbiologyHepatitis CRecombinant ProteinsHost-Pathogen InteractionMultidisciplinary SciencesPhysiological ParametersResearch DesignCombinationHost-Pathogen InteractionsVirusesRNA ViralFemaleDrugPathogensHost-Pathogen Interactions/drug effectsResearch ArticleAdultNeutropeniaClinical Research DesignResearch and Analysis MethodsOutcome Assessment (Health Care)Internal medicineRibavirinRecombinant Proteins/adverse effectsRNA Viral/bloodAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding TreatmentAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Medicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Proportional Hazards ModelsAntiviral Agentbusiness.industryRibavirinBody WeightHepacivirus/drug effectsViral pathogensInterferon-alphaHepatitis C Chronicbiology.organism_classificationHepatitis virusesMicrobial pathogensRNAAdverse EventsCohort StudiebusinessPloS one
researchProduct

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

2018

Objectives We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART. Methods Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and normalized by CD4+ T cells. Linear correlation between pre-ART HIV DNA and other continuous markers (HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to s…

0301 basic medicineOncologyCD4-Positive T-LymphocytesMaleHIV InfectionsSettore MED/07chemistry.chemical_compoundHIV InfectionPharmacology (medical)ViralProspective StudiesProspective cohort studyAntiinfective agentAdult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; DNA Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Viral LoadMiddle AgedViral LoadvirologyHIV CD4Stavudinemedicine.anatomical_structureInfectious DiseasesTreatment Outcomehiv-1 t-lymphocytes virology blood hiv rna hiv dnaAnti-Retroviral AgentsCD4-Positive T-Lymphocyteblood hiv rnaCohorthiv dnaFemaleSurvival AnalysiViral loadARTHumanMicrobiology (medical)Adultmedicine.medical_specialtyAntiretroviral Therapy CD4 Lymphocyte Count StavudineT cellAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesInternal medicinemedicineHumanst-lymphocytesSurvival analysisPharmacologybusiness.industryProportional hazards modelHIVDNASurvival AnalysisCD4 Lymphocyte CountProspective Studie030104 developmental biologychemistryDNA ViralHIV-1Anti-Retroviral AgentbusinessDNA
researchProduct

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

2013

Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population.128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 μg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisa…

AdultMaleHBsAgmedicine.medical_specialtyHepatitis B virusTime FactorsAnti-HIV Agentsmedicine.disease_causeGastroenterologyAntiviral AgentsGroup Blaw.inventionPolyethylene GlycolsPharmacotherapyHepatitis B ChronicRandomized controlled triallawPegylated interferonInternal medicinemedicineHumansHepatitis B e AntigensHepatitis B virusbusiness.industryGastroenterologyLamivudineInterferon-alphaAlanine TransaminaseHepatitis BMiddle Agedmedicine.diseaseHepatitis BRecombinant ProteinsTreatment OutcomeLamivudineImmunologyDNA ViralInterferonDrug Therapy CombinationFemaleHepatitis B; Interferonbusinessmedicine.drug
researchProduct

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

2010

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Liver CirrhosisANTIVIRAL TREATMENTHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusANTIVIRAL THERAPY; PEGYLATED INTERFERON-ALPHA-2B; LIVER-TRANSPLANTATION; PEGINTERFERON ALPHA-2A; HIV-INFECTED PATIENTS; VIRUS-COINFECTED PATIENTS; RAPID VIROLOGICAL RESPONSEAntiviral therapymedicine.disease_causeGastroenterologyPolyethylene GlycolsHBVguidelinesAcute hepatitisChronic hepatitisSettore MED/12 - Gastroenterologialiver transplantationGastroenterologyAntiviral therapyHepatitis CVIRUS-COINFECTED PATIENTSLIVER-TRANSPLANTATIONHepatitis CRecombinant Proteinsacute hepatitis; antiviral therapy; chronic hepatitis; cirrhosis; elderly patients; hbv; hcv; hdv; hiv; liver transplantationCLINICAL PRACTICE GUIDELINESCirrhosisHCVDrug Therapy CombinationAntiviral therapy Acute hepatitis Chronic hepatitisCirrhosis Elderly patients HBV HCV HDV HIV Liver transplantationElderly patientAcute hepatitiAcute hepatitismedicine.medical_specialtyGenotypePEGINTERFERON ALPHA-2AAlpha interferonHIV-INFECTED PATIENTSInterferon alpha-2CHRONIC HEPATITIS CAntiviral AgentsHepatitis B ChronicChronic hepatitisInternal medicineHDVDrug Resistance ViralRibavirinmedicineHumansPEGYLATED INTERFERON-ALPHA-2BCirrhosiHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAInterferon-alphaHIVHepatitis C Chronicmedicine.diseaseElderly patientsFamily medicineExpert opinionAntiviral therapy; Acute hepatitis; Chronic hepatitis; Cirrhosis; Elderly patients; HBV; HCV; HDV; HIV; liver transplantationChronic hepatitiRAPID VIROLOGICAL RESPONSEbusinessCHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; CLINICAL PRACTICE GUIDELINES
researchProduct

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/…

2017

Background: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens. Objectives: We aimed to explore the efficacy and tolerability of switching to darunavir/ritonavir (DRV/r) plus raltegravir (RAL) while having a viral load (VL) ≤50 copies/mL in the clinical setting. Study design: Treatment-experienced HIV 1-infected patients enrolled in the ICONA Foundation Study cohort were included if they switched their current regimen to DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Different defin…

0301 basic medicineMaleHIV InfectionsAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability; Microbiology (medical); Infectious DiseasesAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability; Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; RNA Viral; Raltegravir Potassium; Ritonavir; Viral LoadGastroenterologyCohort StudiesAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability0302 clinical medicineMedicineNRTI-sparing regimen030212 general & internal medicineViralDarunavireducation.field_of_studyLamivudineGeneral MedicineMiddle AgedViral LoadTolerabilityAntiretroviral therapyInfectious DiseasesTolerabilityItalyCombinationRNA ViralDrug Therapy CombinationFemaleViral loadmedicine.drugAdultMicrobiology (medical)medicine.medical_specialtyEfficacyAnti-HIV Agents030106 microbiologyPopulationDarunavir/ritonavir; Raltegravir; Efficacy; Tolerability; Antiretroviral therapy; NRTI-sparing regimenSettore MED/17 - MALATTIE INFETTIVELower riskNO03 medical and health sciencesDrug TherapyInternal medicineRaltegravir PotassiumHumanseducationDarunavirRitonavirbusiness.industryDarunavir/ritonavirRaltegravirRaltegravirHIV-1RNARitonavirbusinessAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability;
researchProduct

Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

2008

The extent to which HIV-1 proviral DNA mutations cause clinically relevant antiretroviral resistance is still controversial. Paired plasma HIV-1 RNA and whole blood DNA were compared in patients failing HAART to investigate if the additional knowledge of archived mutations could improve the selection of potentially active drugs. Seventy-three HIV-1-infected patients with first/second HAART failure were studied before starting a new regimen based on RNA genotyping. Follow-up data after a 12-week therapy were available. DNA genotyping was retrospectively performed on stored whole blood samples and mutational profiles were compared to those from RNA. The mean number of IAS pol mutations was si…

Anti-HIV AgentsDNA Mutational AnalysisMolecular Sequence DataProviral DNAHIV InfectionsHAART failuremedicine.disease_causeDNA Mutational Analysichemistry.chemical_compoundHIV ProteaseProvirusesAntiretroviral Therapy Highly ActiveVirologyDrug Resistance ViralDNA Mutational AnalysismedicineHumansMulticenter Studies as TopicHIV InfectionTreatment FailureGenotypingRandomized Controlled Trials as TopicCOLD-PCRMutationPlasma RNAbiologyProviruseSequence Analysis RNAAnti-HIV AgentRNASequence Analysis DNAbiology.organism_classificationVirologyHIV Reverse TranscriptaseReverse transcriptaseAntiretroviral genotypic resistanceInfectious DiseaseschemistryDNA ViralMutationLentivirusImmunologyHIV-1RNA ViralDNAantiretroviral genotypic resistance; haart failure; hiv-1; plasma rna; proviral dnaHumanJournal of Medical Virology
researchProduct